Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL20595183

N#Cc1cc(C(F)(F)F)cnc1OCCN.O=C(O)C(F)(F)F

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.38
MALT1 Q9UDY8 1/20 0.38
SMN1; SMN2 Q16637 5/20 0.37
AGBL2 Q5U5Z8 1/20 0.36
ACACB O00763 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.35
ALDH1A1 P00352 2/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 2/20 0.34
KDM4E B2RXH2 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
MAPT P10636 1/20 0.34
XBP1 P17861 1/20 0.34
GLA P06280 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22809638 0.91 CYP11B1 (0.39) TRPM8MALT1SMN1; SMN2ACACBALDH1A1
SCHEMBL28354395 0.81 ACACB (0.37) TRPM8MALT1SMN1; SMN2AGBL2ACACB
SCHEMBL8986399 0.81 PTGDR2 (0.45) TRPM8SMN1; SMN2AGBL2ACACBMRGPRX4
SCHEMBL28999026 0.76 PDK2 (0.40) ACACB
SCHEMBL22809399 0.72 CYP1A2 (0.38) SMN1; SMN2AGBL2ALDH1A1KDM4ETDP1
SCHEMBL28882909 0.71 ACACB (0.40) TRPM8SMN1; SMN2AGBL2ACACBHPGD
Hydrochloric Acid SCHEMBL28354555 0.71 IDO1 (0.38) SMN1; SMN2ALDH1A1KDM4ETDP1CYP1A2
SCHEMBL10460598 0.71 CYP1A2 (0.40) MALT1ACACBALDH1A1GAAHPGD
Hydrochloric Acid SCHEMBL30449797 0.71 IDO1 (0.38) SMN1; SMN2ALDH1A1KDM4ETDP1CYP1A2
SCHEMBL16592103 0.70 CYP1A2 (0.52) SMN1; SMN2MRGPRX4ALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN disclosed
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2021-10-26 US disclosed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP disclosed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN disclosed
EP-3487839-A1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RaQualia Pharma Inc. (JP) 2019-05-29 EP disclosed
WO-2018235851-A1 AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS RAQUALIA PHARMA INC. (JP) 2018-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers SCN8A, SCN7A, SCN1A TRPM8 74/4885MALT1 3439/4885SMN1; SMN2 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.